Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors.
The effects of peroxisome proliferator activated receptors alpha and gamma (PPAR-alpha and PPAR-gamma) and retinoid X receptor (RXR) agonists upon synthesis and accumulation of lipids in murine C57Bl macrophages during inflammation induced by injection of zymosan and Escherichia coli lipopolysaccharide (LPS) have been studied. It is significant that intraperitoneal injection of zymosan (50 mg/kg) or LPS (0.1 mg/kg) in mice led to a dramatic increase of [14C]oleate incorporation into cholesteryl esters and triglycerides and [14C]acetate incorporation into cholesterol and fatty acids in peritoneal macrophages. Lipid synthesis reached its maximum rate 18-24 h after injection and was decreased 5-7 days later to control level after LPS injection or was still heightened after zymosan injection. In macrophages obtained in acute phase of inflammation (24 h), degradation of 125I-labeled native low density lipoprotein (NLDL) was 4-fold increased and degradation of 125I-labeled acetylated LDL (AcLDL) was 2-3-fold decreased. Addition of NLDL (50 microg/ml) or AcLDL (25 microg/ml) into the incubation medium of activated macrophages induced 9-14- and 1.25-fold increase of cholesteryl ester synthesis, respectively, compared with control. Addition of NLDL and AcLDL into the incubation medium completely inhibited cholesterol synthesis in control macrophages but had only slightly effect on cholesterol synthesis in activated macrophages. Injection of RXR, PPAR-alpha, or PPAR-gamma agonists--9-cis-retinoic acid (5 mg/kg), bezafibrate (10 mg/kg), or rosiglitazone (10 mg/kg), respectively--30 min before zymosan or LPS injection led to significant decrease of lipid synthesis. Ten hour preincubation of activated in vivo macrophages with the abovementioned agonists (5 microM) decreased cholesteryl ester synthesis induced by NLDL and AcLDL addition into the cell cultivation medium. The data suggest that RXR, PPAR-alpha, or PPAR-gamma agonists inhibited lipid synthesis and induction of cholesteryl ester synthesis in inflammatory macrophages caused by capture of native or modified LDL.
Posokhova
E N
EN
Institute of Internal Medicine, Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russia.
Khoshchenko
O M
OM
Chasovskikh
M I
MI
Pivovarova
E N
EN
Dushkin
M I
MI
D019342:Acetic Acid / Q000378:metabolism; D000818:Animals; D002784:Cholesterol / Q000096:biosynthesis / Q000737:chemistry; D002788:Cholesterol Esters / Q000096:biosynthesis / Q000737:chemistry; D005227:Fatty Acids / Q000096:biosynthesis; D007249:Inflammation / Q000139:chemically induced / Q000378:metabolism*; D008055:Lipids / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008077:Lipoproteins, LDL / Q000378:metabolism; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D019301:Oleic Acid / Q000378:metabolism; D047493:PPAR alpha / Q000819:agonists; D047495:PPAR gamma / Q000819:agonists; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D047488:Retinoid X Receptors / Q000819:agonists*; D014280:Triglycerides / Q000096:biosynthesis / Q000737:chemistry; D015054:Zymosan / Q000008:administration & dosage
D002788:Cholesterol Esters; D005227:Fatty Acids; D008055:Lipids; D008070:Lipopolysaccharides; D008077:Lipoproteins, LDL; D047493:PPAR alpha; D047495:PPAR gamma; D047492:Peroxisome Proliferator-Activated Receptors; D047488:Retinoid X Receptors; D014280:Triglycerides; C032629:acetyl-LDL; D019301:Oleic Acid; D015054:Zymosan; D002784:Cholesterol; D019342:Acetic Acid